塞来昔布衍生物AR-12体外抗四种登革病毒血清型的潜力探索
本研究在Vero细胞中评估塞来昔布衍生物AR-12对四种登革病毒血清型体外复制的抑制效果,采用病毒产量减少试验和qRT-PCR定量病毒RNA。结果显示AR-12对DENV-3抑制最强,依次为DENV-1、DENV-2和DENV-4;分子对接提示其可能通过干扰热休克蛋白的伴侣活性发挥作用。
要点
- AR-12在体外对四种登革病毒血清型均有抑制活性,对DENV-3抑制最强。
- 抑制效果排序为DENV-3>DENV-1>DENV-2>DENV-4。
- 分子对接提示AR-12可能通过干扰热休克蛋白伴侣活性发挥抑制作用。
核心结论
- AR-12在体外对四种登革病毒血清型均显示抑制活性,其中对DENV-3抑制最强。
- 分子对接提示AR-12可能通过干扰热休克蛋白的伴侣活性发挥抑制效果。
研究设计与样本
- 在24孔板中培养Vero细胞,分别感染四种登革病毒血清型后给予不同剂量的AR-12处理。
- 孵育48小时后,通过病毒产量减少试验结合qRT-PCR定量上清中登革病毒RNA拷贝数评估抑制效果。
- 对多个潜在的人源和登革病毒蛋白结构域进行分子对接,探究可能的抑制机制。
主要发现
- qRT-PCR数据显示AR-12对DENV-3抑制最强,其次为DENV-1、DENV-2和DENV-4。
- 分子对接结果表明AR-12可能通过干扰热休克蛋白的伴侣活性发挥抑制作用。
临床怎么用
- 结果为后续体外机制研究和动物模型研究提供基础信息,以评估AR-12作为登革病毒感染潜在治疗选择的可能。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: With no clinically effective antiviral options available, infections and fatalities associated with dengue virus (DENV) have reached an alarming level worldwide. We have designed this study to evaluate the efficacy of the celecoxib derivative AR-12 against the in vitro replication of all four DENV serotypes. METHODS: Each 24-well plate of Vero cells infected with all four DENV serotypes, singly, was subjected to treatments with various doses of AR-12. Following 48 h of incubation, inhibitory efficacies of AR-12 against the different DENV serotypes were evaluated by conducting a virus yield reduction assay whereby DENV RNA copy numbers present in the collected supernatant were quantified using qRT-PCR. The underlying mechanism(s) possibly involved in the compound's inhibitory activities were then investigated by performing molecular docking on several potential target human and DENV protein domains. RESULTS: The qRT-PCR data demonstrated that DENV-3 was most potently inhibited by AR-12, followed by DENV-1, DENV-2 and DENV-4. Our molecular docking findings suggested that AR-12 possibly exerted its inhibitory effects by interfering with the chaperone activities of heat shock proteins. CONCLUSIONS: These results serve as vital information for the design of future studies involving in vitro mechanistic studies and animal models, aiming to decipher the potential of AR-12 as a potential therapeutic option for DENV infection.
引用
- Hassandarvish P, Oo A, Jokar A, et al. Exploring the in vitro potential of celecoxib derivative AR-12 as an effective antiviral compound against four dengue virus serotypes. J Antimicrob Chemother. 2017. PMID: 28666323. doi:10.1093/jac/dkx191
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。